Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC

Sovran Advisors LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,619 shares of the biopharmaceutical company’s stock after selling 2,519 shares during the quarter. Sovran Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $6,395,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its stake in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $226,000. M&T Bank Corp boosted its stake in Regeneron Pharmaceuticals by 16.6% in the second quarter. M&T Bank Corp now owns 5,929 shares of the biopharmaceutical company’s stock valued at $3,113,000 after acquiring an additional 843 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $3,183,000. Finally, Kennedy Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.8% during the second quarter. Kennedy Capital Management LLC now owns 5,106 shares of the biopharmaceutical company’s stock valued at $2,681,000 after purchasing an additional 90 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $761.85 on Friday. The firm has a market capitalization of $80.54 billion, a price-to-earnings ratio of 18.33, a price-to-earnings-growth ratio of 2.02 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The stock’s fifty day moving average is $766.62 and its 200-day moving average is $713.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $12.07 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EYLEA HD (aflibercept) received FDA approval with extended dosing intervals up to five months for wAMD and DME — this can raise lifetime patient value, reduce treatment burden, and boost Regeneron’s retina revenue and competitive positioning. EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
• Positive Sentiment: Regeneron struck a strategic collaboration with TriNetX to access ~300 million de‑identified EHR records, giving it broader phenotypic linkage to its genomic/proteomic datasets — this should accelerate target discovery, improve clinical-trial design, and strengthen AI-driven drug development over time. Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
• Positive Sentiment: Analyst commentary and Zacks/Yahoo pieces highlight Regeneron’s strong earnings‑surprise history and factors that point to another potential beat — supporting short‑term investor optimism ahead of upcoming results. Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Regeneron told investors it expects to be excluded from the U.S. list facing proposed pharma tariffs — that reduces near‑term policy risk and potential margin pressure relative to peers. Regeneron says it expects to avoid new US pharma tariffs
• Neutral Sentiment: Piper Sandler has initiated coverage of Regeneron (details of the call/rating were not in the summary) — coverage can increase attention/liquidity but the impact depends on the firm’s stated rating and model. Piper Sandler Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Analyst Upgrades and Downgrades

REGN has been the topic of several recent research reports. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Barclays began coverage on Regeneron Pharmaceuticals in a research note on Friday, March 6th. They issued an “overweight” rating and a $923.00 target price on the stock. Finally, Zacks Research downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $804.70.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.